Want to see VIR full AI Analyst Report?
VIR Stock Chart & Stats
$11.08
$0.21(2.47%)
At close: 4:00 PM EDT
$11.08
$0.21(2.47%)
Day’s Range― - ―
52-Week Range$4.75 - $11.94
Previous CloseN/A
Volume776.97K
Average Volume (3M)1.74M
Market Cap
$1.94B
Enterprise Value$1.28K
Total Cash (Recent Filing)$528.59M
Total Debt (Recent Filing)$93.27M
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Oct 29, 2026EPS Estimate
-0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.85
Shares Outstanding169,215,960
10 Day Avg. Volume2,218,343
30 Day Avg. Volume1,743,256
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.09
Price to Sales (P/S)12.18
P/FCF Ratio-2.11
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$21.29Price Target Upside92.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.75
Revenue Forecast (FY)$221.91M
Bulls Say, Bears Say
Bulls Say
Durable Clinical Differentiation In Hepatitis DeltaThe combination’s durable viral-clearance signal and superiority to monotherapy support meaningful clinical differentiation. If confirmed in Phase III, this could strengthen regulatory positioning, physician adoption and the long-term commercial potential of Vir’s lead program.
Phase III Execution And Manufacturing ReadinessCompleting enrollment across the registrational program reduces a major development risk and establishes defined readouts for 2026-2027. Completed drug-substance qualification and advancing drug-product PPQ also improve the pathway toward scalable commercial supply.
Strong Liquidity And Strategic Partnership FundingThe substantial cash balance and extended runway provide flexibility to fund late-stage hepatitis programs and oncology expansion without immediate reliance on capital markets. Astellas funding and collaboration also validate strategic interest in Vir’s platform and assets.
Bears Say
Persistent Operating Losses And Cash ConsumptionVir continues to consume cash while funding multiple clinical and platform programs, and its recent earnings recovery has not established sustainable profitability. Prolonged losses could reduce financial flexibility over time and increase dilution or financing risk.
Revenue Remains Lumpy And Collaboration-dependentUpfront and milestone payments can materially improve individual periods but do not represent recurring product demand. Dependence on collaboration recognition makes reported revenue and earnings volatile until Vir develops durable commercial sales or royalty streams.
Commercial Adoption And Execution Risks Remain MaterialLimited disease diagnosis constrains the addressable treated population and could slow uptake even if clinical results succeed. At the same time, senior leadership vacancies and recent turnover create execution risk as Vir advances regulatory, manufacturing and commercial activities.
Vir Biotechnology News
VIR FAQ
What was Vir Biotechnology’s price range in the past 12 months?
Vir Biotechnology lowest stock price was $4.75 and its highest was $11.94 in the past 12 months.
What is Vir Biotechnology’s market cap?
Vir Biotechnology’s market cap is $1.94B.
When is Vir Biotechnology’s upcoming earnings report date?
Vir Biotechnology’s upcoming earnings report date is Oct 29, 2026 which is in 54 days.
How were Vir Biotechnology’s earnings last quarter?
Vir Biotechnology released its earnings results on Aug 05, 2026. The company reported $0.47 earnings per share for the quarter, beating the consensus estimate of $0.333 by $0.137.
Is Vir Biotechnology overvalued?
According to Wall Street analysts Vir Biotechnology’s price is currently Undervalued.
Does Vir Biotechnology pay dividends?
Vir Biotechnology does not currently pay dividends.
What is Vir Biotechnology’s EPS estimate?
Vir Biotechnology’s EPS estimate is -0.74.
How many shares outstanding does Vir Biotechnology have?
Vir Biotechnology has 169,215,960 shares outstanding.
What happened to Vir Biotechnology’s price movement after its last earnings report?
Vir Biotechnology reported an EPS of $0.47 in its last earnings report, beating expectations of $0.333. Following the earnings report the stock price went down -3.787%.
Which hedge fund is a major shareholder of Vir Biotechnology?
Currently, no hedge funds are holding shares in VIR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vir Biotechnology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.29 (92.11% Upside)
$21.29 (92.11% Upside)
Blogger Sentiment
Bullish
VIR Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 476.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
121.49%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.87%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Vir Biotechnology
Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
VIR Company Deck
VIR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed strong clinical and commercial progress (notably robust SOLSTICE Week 96 efficacy, completion of registrational enrollment for ECLIPSE, manufacturing milestones for drug substance, a strengthened balance sheet with ~ $1.01B cash and substantive Astellas funding, and accelerated oncology development with VIR-5500 expansion cohorts). Offsetting risks include higher R&D and SG&A driven by milestone and one-time items, reliance on collaboration revenue for near-term profitability, low current HDV diagnosis rates that could limit short-term market uptake, remaining CMC/drug product activities, and ongoing C-suite hiring. On balance, the positives (clinical data, enrollment completion, cash runway, strategic partnerships and oncology momentum) materially outweigh the near-term operational and market risks.View all VIR earnings summariesVIR Stock 12 Month Forecast
Average Price Target
$21.29
▲(92.11% Upside)
Technical Analysis
Ownership Overview
10.08% Insiders
13.82% Mutual Funds
29.86% Other Institutional Investors
21.74% Public Companies and
Individual Investors